Lion TCR Announces FDA IND Clearance for its LioCyx-M004 for Hepatocellular Carcinoma

SINGAPORE and Guangzhou, China and LOS ANGELES: SINGAPORE and Guangzhou, China and LOS ANGELES, Sept. 23, 2021 /PRNewswire/ -- Lion TCR Pte Ltd, a clinical-stage biotech company specialized in T Cell Receptor (TCR) T cell therapy today announced that it has received clearance from U.S. Food and Drug Administration (FDA)...

Click to view original post